Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium.

Blood Cancer Journal
J M Sánchez-MaldonadoJ Sainz

Abstract

The purpose of this study was to conduct a two-stage case control association study including 654 acute myeloid leukaemia (AML) patients and 3477 controls ascertained through the NuCLEAR consortium to evaluate the effect of 27 immune-related single nucleotide polymorphisms (SNPs) on AML risk. In a pooled analysis of cohort studies, we found that carriers of the IL13rs1295686A/A genotype had an increased risk of AML (PCorr = 0.0144) whereas carriers of the VEGFArs25648T allele had a decreased risk of developing the disease (PCorr = 0.00086). In addition, we found an association of the IL8rs2227307 SNP with a decreased risk of developing AML that remained marginally significant after multiple testing (PCorr = 0.072). Functional experiments suggested that the effect of the IL13rs1295686 SNP on AML risk might be explained by its role in regulating IL1Ra secretion that modulates AML blast proliferation. Likewise, the protective effect of the IL8rs2227307 SNP might be mediated by TLR2-mediated immune responses that affect AML blast viability, proliferation and chemorresistance. Despite the potential interest of these results, additional functional studies are still warranted to unravel the mechanisms by which these variants modulate ...Continue Reading

References

May 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ian SabroeMoira K B Whyte
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J J Waugh, Catherine Wilson
Sep 24, 2010·The New England Journal of Medicine·Miriam F MoffattUNKNOWN GABRIEL Consortium
Jan 31, 2012·Journal of the National Cancer Institute·Kevin Y UrayamaJames D McKay
May 9, 2012·Frontiers in Immunology·Laura Oliveira-NascimentoLee M Wetzler
Aug 28, 2012·The Journal of Clinical Investigation·Thomas JamiesonOwen J Sansom
Jul 16, 2013·International Journal of Cancer. Journal International Du Cancer·Ke LiZhuo-Wei Hu
Sep 18, 2013·Breast Cancer Research : BCR·Jagdeep K SinghRobert B Clarke
Mar 16, 2016·Scientific Data·Mark D WilkinsonBarend Mons
May 18, 2016·Nature Genetics·Joseph K PickrellDavid A Hinds
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Dec 6, 2016·Gene·Wulin ShanFang Deng
Nov 1, 2018·The New England Journal of Medicine·Matthew J ChristopherJohn F DiPersio
Apr 3, 2020·The Journal of Clinical Investigation·Luca Vago, Ivana Gojo

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
ELISA

Software Mentioned

Regulome
Quanto
R
NL
MOLGENIS

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.